The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their association with clinical outcomes. Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clinical outcome benefits.
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
woshi123
v0id
yzy
cdercder
Kao
22336
云城
整齐的慕卉
乐空思
科研狗
yjh123
xing_xing
lixinglei
aaaa
丰富语蕊
XLL小绿绿
GingerF
OK
Oracle
皖公网安备34019202002308
